To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

  • STATUS
    Recruiting
  • End date
    Dec 1, 2022
  • participants needed
    256
  • sponsor
    Genentech, Inc.
Updated on 27 July 2022
cancer
measurable disease
breast cancer
growth factor
metastasis
pertuzumab
epidermal growth factor receptor
HER2
trastuzumab
PIK3CA
fulvestrant
erbb2
epidermal growth factor
palbociclib
her2/neu-positive breast cancer
letrozole
breast cancer staging
mammogram
her2/neu-negative breast cancer

Summary

This is an open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, and pharmacokinetics of inavolisib administered orally as a single agent in patients with locally advanced or metastatic PIK3CA-mutant solid tumors, including breast cancer, and in combination with standard-of-care endocrine and/or targeted therapies for the treatment of locally advanced or metastatic PIK3CA-mutant breast cancer. Participants will be enrolled in two stages: a dose-escalation stage (Stage I) and an expansion stage (Stage II). Participants will be assigned to one of seven regimens: inavolisib as a single agent (Arm A), inavolisib in combination with palbociclib and letrozole (Arm B), inavolisib in combination with letrozole (Arm C), inavolisib in combination with fulvestrant (Arm D), inavolisib in combination with palbociclib and fulvestrant (Arm E), inavolisib in combination with palbociclib, fulvestrant, and metformin (Arm F), and inavolisib in combination with trastuzumab and pertuzumab (and letrozole or fulvestrant, if applicable (Arm G)).

Details
Condition Breast Cancer, Solid Tumor
Treatment Metformin, Trastuzumab, Letrozole, fulvestrant, Pertuzumab, Palbociclib, GDC-0077, Inavolisib
Clinical Study IdentifierNCT03006172
SponsorGenentech, Inc.
Last Modified on27 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Evaluable or measurable disease per RECIST, Version 1.1 (measurable disease only for Arm D)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy of greater than or equal to (≥) 12 weeks
Adequate hematologic and organ function, including blood counts, liver and kidney function
Stage I Arm A (Inavolisib)
Locally advanced, recurrent, or metastatic, PIK3CA mutant, incurable solid tumor malignancy, including breast cancer
Stages I and II, Arms B and C
Postmenopausal female participants with locally advanced or metastatic PIK3CA-mutant HR+/HER2- breast cancer
Stage II, Arms D, E, or F
Female participants with locally advanced or metastatic PIK3CA-mutant HR+/HER2- breast cancer
Stage II Arm D
Prior treatment with CDK4/6 inhibitor
Stages I and II
Stage II Arm G
All participants must provide tumor tissue from the primary or metastatic tumor site obtained from a prior or new biopsy or surgical procedure for detection of PIK3CA mutation by central laboratory test
Female participants with locally advanced or metastatic PIK3CA-mutant HER2+ breast cancer
Left ventricular ejection fraction 50% or greater

Exclusion Criteria

History of leptomeningeal disease
Type 1 or 2 diabetes requiring anti-hyperglycemic medication
Metaplastic breast cancer
Inability or unwillingness to swallow pills
Malabsorption syndrome or other condition that would interfere with enteral absorption
Known and untreated, or active central nervous system metastases
Uncontrolled pleural effusion or ascites
History of other malignancy within 5 years, except for treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer
History of or active ventricular dysrhythmias or congestive heart failure requiring medication or symptomatic coronary heart disease
Congenital long QT syndrome, prolonged QT interval, or family history of sudden unexplained death or long QT syndrome
Stage II Arms B, C, D, and E only
Any active infection that could impact patient safety or serious infection requiring intravenous antibiotics
Prior treatment with >1 chemotherapy regimen for metastatic disease
Prior treatment with PI3K inhibitor
History of significant toxicity related to mTOR inhibitor requiring treatment discontinuation
Stage II Arms B and E only
Prior CDK4/6 inhibitor treatment
Stage II Arm G only
Current uncontrolled hypertension or unstable angina
History of congestive heart failure, serious cardiac arrhythmia, or recent myocardial infarction
Prior ejection fraction decrease on trastuzumab
Prior cumulative doxorubicin greater than 360 mg/m2
Symptomatic active lung disease
History of significant toxicity related to trastuzumab and/or pertuzumab requiring discontinuation of treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note